JSA, and Lex Consult advise on Inviga Healthcare’s acquisition of stake in Forus Health and TPG NewQuest’s exit from Forus Health.
Forus is a leading ophthalmic technology company renowned for its 3nethra series of eye screening devices that have screened over 22 million patients across 75 countries. Leveraging AI-driven diagnostics, its platform has served over 5 million patients worldwide, advancing early detection and accessibility in eye care. The company’s latest innovation, the 3nethra specto —a smartphone-controlled wearable digital refractor — is redeining tele-optometry and remote vision screening. Forus was recently recognised among TIME Magazine’s World’s Top 400 HealthTech Companies for its contribution to global vision care.
Inviga is developing a differentiated multi-specialty hospital platform while strategically investing in high-potential healthcare and life sciences ventures. Through its dual-track strategy of majority-led hospital roll-ups and minority investments in innovative, IP-driven enterprises, Inviga aims to accelerate scalable healthcare solutions and long-term value creation across the Ecosystem.
JSA Advocates & Solicitors advised Forus Health Private Limited (Forus) and its Co-founder & CEO in a secondary transaction involving the acquisition of a 21% stake in Forus by Inviga Healthcare Fund (Inviga). The JSA Corporate Team comprised Partner Manuel Jose and Senior Associate Harshita Agarwal.
Lex Consult acted for TPG New Quest in the exit from Forus Health Private Limited. The team comprised Nidhi Khadria, Garima Agrawal and Tejas Kandalgaonkar.
The deal reporting on this platform is based on the information received from law firms, and therefore, some details may be missing/incomplete. If your firm has not been credited for this deal, write to us at chanchal.makhija@thegreymatter.co.in mentioning your firm’s name, lawyers involved (including designation) and client represented.
